We Our Hometown News Search
Our Newspaper AdsHG413Submit NewsPlace Classifieds
the reminder, we are hometown news

Schizophrenia and Bipolar Disorder Treatment Agawam MA

The drug Saphris (asenapine) has been approved by the U.S. Food and Drug Administration to treat adults with either schizophrenia or bipolar I disorder, the agency said Friday. Symptoms of schizophrenia may include hearing imagined voices, seeing things that aren't present, and having thoughts that others are going to do you harm in Agawam. This can lead to behavior including withdrawal, extreme fear, and violence.

Aaron Morris Leavitt, MD
413-567-5095
26C Castle Hill Rd
Agawam, MA
Marcelo G Pakman, MD
413-594-2211
273 State St
Springfield, MA
Moris Pardo, MD
413-733-2050
163 Pinewood Dr
Longmeadow, MA
Michelle Kosche Anfang, MD
413-567-7842
120 Pinewood Hls
Longmeadow, MA
H Douglas Barnshaw Jr, MD
413-739-7680
237 Longhill St
Springfield, MA
David Lee Honeyman, MD
413-594-3111
273 State St
Springfield, MA
Yolando P Acuzar, MD
413-736-3668
273 State St
Springfield, MA
Edward Lee Balaban, MD
413-244-8033
1175 Dickinson St
Springfield, MA
Susan Romm Reuben, MD
413-567-2094
296 Concord Rd
Longmeadow, MA
Jay Martin Pomerantz, MD
413-567-1591
123 Dwight Rd
Longmeadow, MA
Data Provided by:
 
Provided By:

Schizophrenia and Bipolar Disorder Treatment

The drug Saphris (asenapine) has been approved by the U.S. Food and Drug Administration to treat adults with either schizophrenia or bipolar I disorder, the agency said Friday.

Symptoms of schizophrenia may include hearing imagined voices, seeing things that aren't present, and having thoughts that others are going to do you harm. This can lead to behavior including withdrawal, extreme fear, and violence.

People with bipolar I have alternating periods of depression and manic highs. Other symptoms may include restlessness, racing thoughts, and impulsive behavior.

Saphris is among a class of drugs called atypical antipsychotics, all of which must be labeled with the FDA's most serious "black box" warning, the agency said in a news release. The label warns of increased risk of death if the drugs are used by older people with dementia-related psychosis. These drugs aren't approved for this so-called "off-label" use.

Common adverse reactions recorded during clinical testing of Saphris included an inability to sit still (akathisia) and other movement disorders, drowsiness, decreased sensitivity in and around the mouth, and weight gain, the FDA said.

Saphris is produced by New Jersey-based Schering-Plough.

More information

The FDA has additional information about this approval.

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Reminder Publications, Inc. 280 North Main St., East Longmeadow, MA 01028 • Ph 413.525.6661 • fax 413.525.5882
Archives Search Advertiser Info Contact Us Home